NCT02628067View on ClinicalTrials.gov

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

1,609

Participants

Timeline

Start Date

December 18, 2015

Primary Completion Date

May 4, 2027

Study Completion Date

May 4, 2027

Conditions
Advanced CancerAnal CarcinomaAnal CancerBiliary CancerCholangiocarcinomaBile Duct CancerNeuroendocrine TumorCarcinoid TumorEndometrial CarcinomaEndometrial CancerCervical CarcinomaCervical CancerVulvar CarcinomaVulvar CancerSmall Cell Lung CarcinomaSmall Cell Lung Cancer (SCLC)MesotheliomaThyroid CarcinomaThyroid CancerSalivary Gland CarcinomaSalivary Gland CancerSalivary CancerParotid Gland CancerAdvanced Solid TumorsColorectal Carcinoma
Interventions
BIOLOGICAL

pembrolizumab

intravenous infusion

BIOLOGICAL

pembrolizumab

intravenous infusion

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY